Clinical Trial Update: Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) [Phase 2]

View source ↗

Summary

Phase 2 XanaCIDD trial evaluating Xanamem in adults with major depressive disorder and cognitive impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment
• Major Depressive Disorder

Drugs mentioned

• Xanamem

Snippet

Sponsor: Actinogen Medical | Conditions: Major Depressive Disorder, MDD | Phase 2 | Status: COMPLETED